2x founder

Jasper Edgar Neggers

Co-founder & CSO | Promakhos Therapeutics | Ph.D.

Co-founder

Promakhos Therapeutics· Summer 2021 Greater Boston

in LinkedIn

2021Co-founder· Promakhos Therapeutics

Founder · since 2009

Company

Promakhos Therapeutics

Role

Co-Founder, Chief Scientific Officer, Secretary

current

Stage

—

no public source

Raised

—

no public source

Based

United States of America, Massachusetts, Allston

current

Founder / co-founder — the company's markEmployee / research role

Source: LinkedIn work history

Profile coverage5 of 7 · missing posts, contact

Promakhos Therapeutics

A therapeutics platform for curing inflammatory disorders

Summer 2021

Experience

Career

Promakhos Therapeutics
Co-founder
Co-Founder, Chief Scientific Officer, Secretary · United States of America, Massachusetts, Allston · 2021 – Present
2021
Dana-Farber Cancer Institute
Postdoctoral Research Fellow · United States of America, Massachusetts, Boston · 2018 – 2021
2018
Harvard Medical School
Instructor (NCI K99/R00 awardee) · United States of America, Massachusetts, Boston · 2021
2021
Harvard Medical School
Postdoctoral Research Fellow · United States of America, Massachusetts, Boston · 2018 – 2021
2018
Damon Runyon Cancer Research Foundation
Damon Runyon Postdoctoral Research Fellow · United States of America, NY, City of New York · 2019 – 2021
2019
Broad Institute of MIT and Harvard
Visiting Research Fellow/Affiliate Scientist · United States of America, Massachusetts, Cambridge · 2018 – 2021
2018
Harvard University
Teaching Fellow · Cambridge, Massachusetts, United States · 2020
2020
Miniprise VOF
Co-founder
Co-Founder & Web Developer · Netherlands · 2009 – 2010
2009

Bio

CSO and co-founder of Promakhos. In high school, Jasper built a web-shop. He obtained a BSc, MSc and PhD in Biomedical Sciences from KU Leuven. He pioneered the use of XPO1 inhibitors for treating cancer and invented a CRISPR-directed evolution technology for drug target deconvolution. Jasper then joined the Dana-Farber Cancer Institute & Broad Institute of MIT and Harvard to identify and validate new drug targets for gastrointestinal cancers. Now, he develops drugs for chronic inflammation.